{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:14:22Z","timestamp":1740176062755,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Neurosurg Jl"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pituitary apoplexy is a neurosurgical emergency and is a known yet rare complication of pituitary macroadenoma. Patients typically present with visual field defects, headache and altered sensorium. There are multiple risk factors for this complication and a thorough drug history is essential to exclude iatrogenic causes of disease. We present an extremely rare case of newly diagnosed pituitary insufficiency unveiled by ibrutinib therapy (a Bruton tyrosine kinase inhibitor). Furthermore, after initial withdrawal of ibrutinib because of the erroneous diagnosis of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), its re-administration led to the development of classical pituitary apoplexy 4\u00a0months after treatment was restarted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A male patient in his 60s with a background of chronic lymphocytic leukaemia (CLL) on ibrutinib and venetoclax presents with acute confusion and deranged electrolytes. He is found to be hyponatraemic and is diagnosed with Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and treated with fluid restriction. He represents again 3\u00a0weeks later with hyponatraemia and further investigations reveal pituitary insufficiency and macroadenoma. He was restarted on ibrutinib and venetoclax at the time of discharge.<\/jats:p>\n                <jats:p>Four months later, he presents with sudden retro-orbital headache associated with vomiting. Clinical findings include cranial nerve III, IV and XI palsy. Humphrey\u2019s visual field examination revealed a left visual field index (VFI) of only 1% while the right was 64% with temporal hemianopia. Both pupils were mid-dilated and poorly reactive to light. MRI pituitary with contrast showed features of pituitary apoplexy and optic nerve compression. He was urgently referred to the neurosurgical team and underwent an emergency trans-sphenoidal hypophysectomy with circumferential excision of the macroadenoma. Post-operative recovery was uneventful with marked improvement in vision bilaterally.<\/jats:p>\n                <jats:p>The patient was restarted on ibrutinib and venetoclax 2\u00a0weeks post-operatively. Approximately 1\u00a0year post-treatment, he remains in radiological, clinical and biochemical remission from CLL and all medications have been withdrawn.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is a unique and rare case of pituitary macroadenoma apoplexy following the commencement of ibrutinib for CLL. Central nervous system haemorrhage is a rare side effect of ibrutinib due to its platelet dysfunction effects. A thorough assessment is required to assess the risks and benefits of using ibrutinib in patients with pituitary macroadenoma to avoid serious complications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41016-023-00345-0","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T04:02:15Z","timestamp":1698120135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pituitary macroadenoma apoplexy as a rare complication of Bruton tyrosine kinase inhibitor in chronic lymphoid leukaemia"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0833-3710","authenticated-orcid":false,"given":"Aysha","family":"Gomaa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Skelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"issue":"5","key":"345_CR1","doi-asserted-by":"publisher","first-page":"R179","DOI":"10.1530\/EJE-14-0794","volume":"172","author":"C Capatina","year":"2015","unstructured":"Capatina C, Inder W, Karavitaki N, et al. Management of endocrine disease: pituitary tumour apoplexy. Eur J Endocrinol. 2015;172(5):R179\u201390. https:\/\/doi.org\/10.1530\/EJE-14-0794.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"345_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1056\/NEJMoa1900574","volume":"381","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;381(8):788\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1900574.","journal-title":"N Engl J Med"},{"issue":"25","key":"345_CR3","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. IBRUTINIB as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1509388.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"345_CR4","doi-asserted-by":"publisher","first-page":"SUN-280","DOI":"10.1210\/jendso\/bvaa046.740","volume":"4","author":"P Guido","year":"2020","unstructured":"Guido P, Treasure M, DeCherney G. SUN-280 a brute of a case: pituitary apoplexy in a patient treated for chronic lymphocytic leukemia with ibrutinib. J Endocr Soc. 2020;4(Supplement_1):SUN-280. https:\/\/doi.org\/10.1210\/jendso\/bvaa046.740.","journal-title":"J Endocr Soc"},{"issue":"11","key":"345_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","volume":"18","author":"J Mock","year":"2018","unstructured":"Mock J, Kunk PR, Palkimas S, et al. Risk of major bleeding with Ibrutinib. Clin Lymphoma Myeloma Leuk. 2018;18(11):755\u201361. https:\/\/doi.org\/10.1016\/j.clml.2018.07.287.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"345_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","volume":"1","author":"F Caron","year":"2017","unstructured":"Caron F, Leong D, Hillis C, et al. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1(12):772\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2016001883.","journal-title":"Blood Adv"},{"key":"345_CR7","doi-asserted-by":"publisher","first-page":"580622","DOI":"10.3389\/fphar.2020.580622","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang J, Zhao A, Zhou H, et al. Risk of bleeding associated with Ibrutinib in patients with B-cell malignancies: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2020;11:580622. https:\/\/doi.org\/10.3389\/fphar.2020.580622.","journal-title":"Front Pharmacol"},{"issue":"3","key":"345_CR8","doi-asserted-by":"publisher","first-page":"e0279634","DOI":"10.1371\/journal.pone.0279634","volume":"18","author":"Y Sugita","year":"2023","unstructured":"Sugita Y, Takada S, Tanigaki K, et al. Inhibition of VEGF receptors induces pituitary apoplexy: an experimental study in mice. PLoS One. 2023;18(3):e0279634. https:\/\/doi.org\/10.1371\/journal.pone.0279634.","journal-title":"PLoS One"},{"key":"345_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6086756","volume":"2021","author":"R Gupta","year":"2021","unstructured":"Gupta R, Bhattacharjee U, Lekshmon KS, Chaudhary S, Sharma P, Jandial A, et al. Acute lymphoblastic leukemia presenting as PITUITARY APOPLEXY: a case report and review of the literature. Case Rep Endocrinol. 2021;2021:1\u20135. https:\/\/doi.org\/10.1155\/2021\/6086756.","journal-title":"Case Rep Endocrinol"},{"issue":"2","key":"345_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/s0317167100042335","volume":"19","author":"JS Fain","year":"1992","unstructured":"Fain JS, Naeim F, Becker DP, Van Herle A, Yan-Go F, Petrus L, et al. Chronic lymphocytic leukemia presenting as a pituitary mass lesion. Can J Neurol Sci. 1992;19(2):239\u201342. https:\/\/doi.org\/10.1017\/s0317167100042335.","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"345_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1158\/1078-0432.CCR-15-2921","volume":"23","author":"N Amin","year":"2017","unstructured":"Amin N, Balasubramanian S, Saiya-Cork K, et al. Cell-intrinsic determinants of ibrutinib-induced apoptosis in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(4):1049\u201359. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2921.","journal-title":"Clin Cancer Res"}],"container-title":["Chinese Neurosurgical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41016-023-00345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41016-023-00345-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41016-023-00345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T10:43:37Z","timestamp":1700390617000},"score":1,"resource":{"primary":{"URL":"https:\/\/cnjournal.biomedcentral.com\/articles\/10.1186\/s41016-023-00345-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1186\/s41016-023-00345-0","relation":{},"ISSN":["2057-4967"],"issn-type":[{"type":"electronic","value":"2057-4967"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written patient consent has been obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}